[Question] does the vial concentration change how much dead space costs me
Question in the title, detail here: does the vial concentration change how much dead space costs me. The distribution matters more than the mean. In the trial population the interquartile spread was wide enough that two honest people can have completely different runs on the same arm. Sulphur burps for the first…
Research-use-only material is not approved for human use. Anything in this thread about how a research vial "should" titrate is a discussion about chemistry, not a plan.
Research-use-only material is not approved for human use.
Saving this one. It is the clearest statement of the stall problem I have read here.
dual agonist, so the GIP arm is doing something the sema threads will not tell you about
Push back: "gentler than sema" is a population statement. Plenty of people on this board have the opposite experience and they are not doing it wrong.
The 21% figure is a 72-week mean on the highest arm. Quoting it as what someone should expect by week 24 is not a fair reading.
2.5 is the starter dose and it is not meant to be the dose that works
That percentage is body weight change, not body fat. Different measurement, and the distinction gets lost every time.
Small fix: SURMOUNT is the obesity programme, SURPASS is the type-2 programme. They are different endpoints and the numbers do not transfer.